CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
31 mai 2016 07h00 HE
|
CymaBay Therapeutics, Inc.
Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacyLarge...